|
Body Temperature Changes
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Oral administration of pioglitazone (PPARγ agonist) significantly suppressed body temperature change of mice in passive systemic anaphylaxis, supporting the inhibitory functions of PPARγ in IgE/Ag-dependent activation of MCs in vivo.
|
31630176 |
2020 |
|
Intrahepatic Cholestasis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Rosiglitazone prevented wild type but not hepatocyte-specific PPARγ deficient mice from ANIT-induced intrahepatic cholestasis by activating expression of bile homeostatic molecules, reducing hepatic necrosis, and correcting abnormal serum parameters and bile enterohepatic circulation.
|
31658492 |
2020 |
|
Hypoglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The incidence of hypoglycemia and PPARγ-agonist-associated events such as edema and fractures were similar in the placebo and MSDC-0602K groups.
|
31697972 |
2020 |
|
Psoriasis vulgaris
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To study the association between PPAR-γ gene polymorphism and psoriasis vulgaris in Egyptian patients to explore if this polymorphism influenced disease risk or clinical presentation.
|
31148857 |
2020 |
|
Biliary Tract Cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Using surgical specimens from 74 BTCs, we performed immunohistochemistry for FABP5 and its associated molecules, including peroxisome proliferator-activated receptor γ (PPARγ), PPARγ coactivator 1 (PGC-1), and estrogen-related receptor α (ERRα).
|
31432248 |
2020 |
|
Inflammatory disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Novel PPARα agonists, PPARδ agonists, PPARγ agonists, PPARα/γ dual agonists, and PPARγ antagonists have been claimed for the treatment of metabolic disease and inflammatory disease.
|
31825687 |
2020 |
|
Primary Myelofibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results indicated that PV dominantly expressed β-catenin and proliferation marker Ki67 in bone marrow, while PMF is linked preferentially to PPAR-γ immunopositive megakaryocytes characterized by abnormal maturation.
|
30582392 |
2019 |
|
Refractory anemias
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Chromatin immunoprecipitation confirmed the direct binding of PPARγ on the promoter region of SCD, with increased binding in the CmpdA/RGZ/RA-treated KGN cells.
|
30706710 |
2019 |
|
Angina, Unstable
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The results of our study suggest the association between PPARG rs1801282 G allele and unstable angina in Polish population.
|
31252163 |
2019 |
|
Autistic Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress.
|
31348919 |
2019 |
|
Infection by Cryptococcus neoformans
|
0.010 |
Biomarker
|
disease |
BEFREE |
15-keto-prostaglandin E2 activates host peroxisome proliferator-activated receptor gamma (PPAR-γ) to promote Cryptococcus neoformans growth during infection.
|
30921435 |
2019 |
|
Dry Eye Syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, the present results indicate that PPARγ and adiponectin-mediated signaling contribute to age-related increases in tear production in mice and have potential as therapeutic targets for the treatment of dry eye in humans.
|
31596727 |
2019 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Modulation of PPAR-γ could be a potential novel treatment for epileptic seizures.
|
30623373 |
2019 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
QSYQ upgraded the expression of IGF-1R, P-AMPK/AMPK, peroxisome proliferator-activated receptor-γ coactivator-1α, nuclear respiratory factor-1, P-phosphatidylinositol 3-kinase (PI3K)/PI3K, and P-Akt/Akt thereby attenuated the dysregulation of IGF-1R signaling after fatigue.
|
30951366 |
2019 |
|
Glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To evaluate the potential antifibrotic effect of rosiglitazone (RSG), a peroxisome proliferator-activated receptor γ (PPARγ)-selective agonist, on subconjunctival fibrosis in a rabbit model of glaucoma filtration surgery (GFS) in vivo, and to investigate the underlying mechanisms in human Tenon's fibroblasts (HTFs) in vitro.
|
31247081 |
2019 |
|
Hepatitis, Alcoholic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In addition, we showed that the expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) was down-regulated in vivo and in vitro in AH.
|
30951781 |
2019 |
|
Hypothyroidism
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Significance</b>: Our finding in the present study indicated that PPARγ agonist pioglitazone prevented the brain tissues from oxidative damage and learning and memory impairments in juvenile hypothyroid rats.
|
31215278 |
2019 |
|
Arthropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
Epigenetic PPARγ suppression plays a key role in OA development and PPARγ preservation via promoter demethylation possesses promising therapeutic potentials in clinical treatment of OA and the related joint diseases.
|
31239244 |
2019 |
|
Kidney Calculi
|
0.010 |
Biomarker
|
disease |
BEFREE |
Peroxisome proliferator-activated receptor γ (PPARγ) has been shown to be critical for the regulation of cell transdifferentiation in many physiological and pathological conditions; however, little is known about its role in kidney stone formation.
|
30317563 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This coincided with decreased levels of peroxisome proliferator-activated receptor γ coactivator 1-α, and in line with that, CLL-derived CD8<sup>+</sup> T cells showed impaired mitochondrial biogenesis upon stimulation.
|
31076448 |
2019 |
|
Spinal Muscular Atrophy
|
0.010 |
Biomarker
|
disease |
BEFREE |
After a single bout of exercise, canonical responses such as skeletal muscle AMP-activated protein kinase (AMPK), p38 mitogen-activated protein kinase (p38) and peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) activation were preserved in SMA-like Smn<sup>2B/-</sup> animals.
|
31361024 |
2019 |
|
Myeloproliferative disease
|
0.010 |
AlteredExpression
|
group |
BEFREE |
β-catenin and PPAR-γ levels in bone marrow of myeloproliferative neoplasm: an immunohistochemical and ultrastructural study.
|
30582392 |
2019 |
|
Nicotine withdrawal
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Results showed that activation of PPARγ by pioglitazone abolished the expression of somatic and affective nicotine withdrawal signs in rats and in (PPARγ<sup>(+/+)</sup>) mice.
|
31685649 |
2019 |
|
Polycythemia Vera
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicated that PV dominantly expressed β-catenin and proliferation marker Ki67 in bone marrow, while PMF is linked preferentially to PPAR-γ immunopositive megakaryocytes characterized by abnormal maturation.
|
30582392 |
2019 |
|
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Oroxylin A inhibits Kaposi's sarcoma-associated herpes virus (KSHV) vIL-6-mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARγ/Prox1 axis.
|
30318784 |
2019 |